Aarti Drugs (NSE:AARTIDRUGS) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 29, 2026)


NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
75 GF Score
Price ₹372.70
GF Value ₹497.01
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Aarti Drugs's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NSE:AARTIDRUGS vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aarti Drugs Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Margin of Safety % (DCF Earnings Based) falls into.


NSE:AARTIDRUGS
75GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹372.70 is trading 25% below its estimated GF Value™ of ₹497.01. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹497.01 vs. price of ₹372.70 (25% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
75GF Score

Get the complete analysis for NSE:AARTIDRUGS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹372.70
Price
₹497.01
GF Value